Sunday, August 03, 2025 8:08:35 AM
Thanks! Great to know this about IRIS.
Here's a Copilot summary of your post:
🧠 What Is IRIS?
- IRIS isn’t a drug—it’s an AI tool that listens to a tumor’s RNA and finds where - the genetic instructions went wrong.
- It uses machine learning to detect unusual RNA splicing patterns that could - - be used to trigger an immune response.
🔬 How Does IRIS Work?
It follows five steps:
1. Scans tumor RNA for abnormal splice variants not found in healthy tissue.
2. Predicts which fragments might be recognized by the immune system.
3. Filters for fragments that are actually visible to immune cells.
4. Manufactures those fragments synthetically.
5. Prepares them for use in DCVax, NWBO’s dendritic cell therapy.
🧬 Why It Matters
- IRIS helps program the immune system to recognize and remember cancer cells.
- It turns DCVax into a rehearsal loop, not just a one-time treatment—building long-term immunity.
👶 Pediatric Focus
- IRIS was designed for childhood cancers where traditional DNA analysis fails.
- It targets rare and aggressive tumors like:
1. DIPG (brainstem tumor)
2. ATRT (rhabdoid tumors)
3. Ependymoma
4. Infantile fibrosarcoma
5.Pediatric kidney and CNS tumors
🧪 Who’s Behind It?
- Invented by top scientists including Dr. Linda Liau, now NWBO’s Chief Scientific Officer.
- Co-owned by University of California and Children’s Hospital of Philadelphia (CHOP)—a strong signal that it’s aimed at pediatric use.
🚀 What’s Next for NWBO?
- NWBO could integrate IRIS with its existing platforms (Eden, Flaskworks).
- This means NWBO may soon offer AI-personalized cancer vaccines for children—without needing chemo, radiation, or surgery.
Here's a Copilot summary of your post:
🧠 What Is IRIS?
- IRIS isn’t a drug—it’s an AI tool that listens to a tumor’s RNA and finds where - the genetic instructions went wrong.
- It uses machine learning to detect unusual RNA splicing patterns that could - - be used to trigger an immune response.
🔬 How Does IRIS Work?
It follows five steps:
1. Scans tumor RNA for abnormal splice variants not found in healthy tissue.
2. Predicts which fragments might be recognized by the immune system.
3. Filters for fragments that are actually visible to immune cells.
4. Manufactures those fragments synthetically.
5. Prepares them for use in DCVax, NWBO’s dendritic cell therapy.
🧬 Why It Matters
- IRIS helps program the immune system to recognize and remember cancer cells.
- It turns DCVax into a rehearsal loop, not just a one-time treatment—building long-term immunity.
👶 Pediatric Focus
- IRIS was designed for childhood cancers where traditional DNA analysis fails.
- It targets rare and aggressive tumors like:
1. DIPG (brainstem tumor)
2. ATRT (rhabdoid tumors)
3. Ependymoma
4. Infantile fibrosarcoma
5.Pediatric kidney and CNS tumors
🧪 Who’s Behind It?
- Invented by top scientists including Dr. Linda Liau, now NWBO’s Chief Scientific Officer.
- Co-owned by University of California and Children’s Hospital of Philadelphia (CHOP)—a strong signal that it’s aimed at pediatric use.
🚀 What’s Next for NWBO?
- NWBO could integrate IRIS with its existing platforms (Eden, Flaskworks).
- This means NWBO may soon offer AI-personalized cancer vaccines for children—without needing chemo, radiation, or surgery.
"Hope deferred makes the heart sick, but a longing fulfilled is a tree of life." - Proverbs 13:12
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
